SPY367.32+0.53 0.14%
DIA300.77+1.59 0.53%
IXIC12,406.59+57.22 0.46%

iRhythm Technologies Reports 3-Year Clinical Outcomes For Atrial Fibrillation Screening Candidate To Be Presented At American Heart Association Sessions Nov. 16 At 10:21 a.m. EST

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that 3-year clinical outcomes in a nationwide, randomized, pragmatic

· 11/13/2020 09:06

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that 3-year clinical outcomes in a nationwide, randomized, pragmatic clinical trial of atrial fibrillation screening – Mhealth Screening to Prevent Strokes (mSToPS) – will be presented at the 2020 American Heart Association (AHA) Scientific Sessions.

Presentation Details

Title: 3-year Clinical Outcomes in a Nationwide, Randomized, Pragmatic Clinical Trial of Atrial Fibrillation Screening - Mhealth Screening to Prevent Strokes (mSToPS)

Presenter: Steven Steinhubl, MD, Scripps Research Translational Institute

Session: To Screen or Not to Screen, and then What? Studies of Detection and Treatment of AF

Date/Time: Monday, November 16, 2020 at 9:21-9:29 a.m. CT

The above presentation will be available to conference registrants for viewing online at the AHA Scientific Sessions’ Virtual Platform at https://professional.heart.org/es/meetings/scientific-sessions.